Van Campen Liem assisted Prilenia Therapeutics in its $62.5M Series A Funding Round. The clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders will use the raised funding to launch the company’s two late-stage clinical trials of pridopidine in Huntington Disease (HD) and Amyotrophic Lateral Sclerosis (ALS).
The Series A round was led by Forbion, and accompanied by Morningside Venture Investments, Sectoral Asset Management, Talisman Capital Ventures and Genworks 2. The Series A financing brings the total capital investment in Prilenia Therapeutics since its foundation in September 2018 to $84.5M. As part of this Series A round, a new Dutch company, Prilenia Therapeutics B.V. has been formed. The new company will hold the Israeli subsidiary company Prilenia Neurotherapeutics Ltd.
The Van Campen Liem team consisted of Edwin Liem (partner), Martina Priekaar (senior-associate) and Anna Zhu (associate).
More information can be found here: https://www.prilenia.com/copy-of-18-september-2019-pr
Edwin Liem, Martina Priekaar and Anna Zhu.
Van Campen Liem Luxembourg, advised the impact investment fund established by George Soros – the Soros Economic Development Fund (SEDF) – on the Luxembourg legal matters in relation to its commitment to the InsuResilience Investment Fund, a private equity impact investment fund established with the objective to invest in companies offering affordable insurance products for smallholders and micro enterprises exposed to climate-related risks, as well as technology platforms that enable the creation and distribution of these insurance products.
SEDF is the social impact investment arm of the Open Society Foundations. The Open Society Foundations is one of the world’s largest private funders of organizations and initiatives. They support human rights, the rule of law, democracy and accountability.
SEDF makes impact investments aimed at creating economic opportunities for those who face systemic discrimination or exclusion. They work with the purpose of supporting the Foundations’ core mission: promoting open, tolerant and democratic societies across the world.
The InsuResilience Investment Fund is managed by BlueOrchard, a leading global private equity impact investing manager. Founded in 2001, BlueOrchard has invested USD 6 billion in over 80 emerging and frontier markets across Asia, Eastern Europe, Latin America and Africa.
SEDF’s investment is part of the final close of the InsuResilience Investment Fund launched in 2017 as a USD 43,000,000 fund with support from the German Development Bank KFW. The final close will raise the fund’s total value to above USD 75,000,000.
The Van Campen Liem team advising SEDF was composed of William Tanguy (partner), Benoit Kelecom (counsel) and Jean Gaspard (associate). The Michelmores team advising SEDF was led by Joe Whitfield, supported by Rory Swanson. The InsuResilience Investment Fund was assisted by Allen & Overy.
William Tanguy, Benoit Kelecom and Jean Gaspard – Van Campen Liem Luxembourg